XML 75 R66.htm IDEA: XBRL DOCUMENT v2.4.0.6
Discontinued Operations The operating results of the Regenerative Medicine - China business (Details) (Regenerative Medicine - China segment [Member], USD $)
12 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Regenerative Medicine - China segment [Member]
   
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Revenue $ 274,300 $ 55,900
Cost of revenues (140,600) (36,000)
Research and development (378,300) (112,400)
Research and development (3,089,900) (1,408,200)
Research and development (9,700) (63,800)
Loss from discontinued operations $ (3,344,200) $ (1,564,500)